LICENSE AGREEMENT BY AND BETWEENLicense Agreement • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of February 20, 2018 (“Effective Date”) between Tetraphase Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with a principal place of business at 480 Arsenal Street, Suite 110, Watertown, MA 02472 (“Tetraphase”), and Everest Medicines Limited, an exempted company organized and existing under the laws of Cayman Islands, with a principal place of business at Suite 4508, 45F, Tower 2, Plaza 66, 1266 Nanjing Xi Lu, Shanghai 200040, China (“Licensee”).
Fourth Amendment to License AgreementLicense Agreement • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances)
This Fourth Amendment to License Agreement (this “Fourth Amendment”) is entered into as of this 5th day of December, 2017 (the “Fourth Amendment Effective Date”), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 480 Arsenal Street, Suite 110, Watertown, MA 02472 (“Licensee”) and President and Fellows of Harvard College, Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”).
Master Manufacturing Services Agreement 14 JUNE 2017Product Agreement • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:
SUBLEASESublease • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Massachusetts
THIS SUBLEASE (this “Sublease”) is made and entered into this 21st day of December, 2020, by and between COTIVITI, INC., a Delaware corporation (“Sublandlord”) and LA JOLLA PHARMACEUTICAL COMPANY, a California corporation (“Subtenant”).
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Licence Agreement • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances)
request stating that Paion and its Affiliates are entitled to make exclusive use of the Licensed Know-how and Programme Data for the purpose of exercising their rights in accordance with this Agreement. La Jolla and the Licensors shall provide the technical and other information described in Clause 2.2 to Paion within thirty (30) days after the Commencement Date.
ContractLa Jolla Pharmaceutical Co • March 8th, 2021 • Biological products, (no disgnostic substances)
This Amendment (“Amendment”) is made and entered into as of July 29, 2019 between Tetraphase Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with a principal place of business at 480 Arsenal Way, Watertown, MA 02472 (“Tetraphase”), and Everest Medicines Limited, an exempted company organized and existing under the laws of Cayman Islands, with a principal place of business at Room 3306-3307, Two Exchange Square, 8 Connaught, Hong Kong (“Licensee”). Reference is made to that certain License Agreement (“Original License Agreement”) dated February 20, 2018 between Tetraphase and Licensee. Capitalized terms used herein without definitions shall have the same meanings ascribed to them under the Original License Agreement.
LICENSE AGREEMENT Between TETRAPHASE PHARMACEUTICALS, INC. And PRESIDENT AND FELLOWS OF HARVARD COLLEGELicense Agreement • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement is entered into as of this 3rd day of August, 2006 (the “Effective Date”), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business c/o Mediphase Venture Partners, 3 Newton Executive Park, Suite 104, Newton, MA 02462 (“Licensee”) and President and Fellows of Harvard College, Holyoke Center, Suite 727, 1350 Massachusetts Ave., Cambridge, MA (“Harvard”). Dr. Andrew G. Myers shall also be party to this Agreement, but solely for purposes of Article 2.
